AKT1 and neoplasm: Those that are overexpressed in OS tissues, enhance tumor progression or drug resistance by promoting PI3K/Akt/mTOR pathway signaling; while, those that are downregulated in tumor tissues, inhibit tumor progression by inhibiting the PI3K/Akt/mTOR pathway.